Customization: | Available |
---|---|
Certification: | ISO 9001, FDA |
Use: | Healthy |
Still deciding? Get samples of US$ 200/kg
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
product name | Lafutidine |
CAS NO. | 118288-08-7 |
Specification | 99% |
Appearance | White powder |
packing | 1kg/bag,25kgs/drum |
MOQ | 1KG |
Pharmacological studies have shown that Lafutidine is a highly effective, long-acting H2 receptor antagonist that has a significant inhibitory effect on gastric acid secretion, and can inhibit gastric acid secretion caused by histamine, pentagastrin, food, etc. This product has a gastric mucosal protective effect, can dose-dependently inhibit the formation of ulcers in a variety of experimental animal ulcer models, promote ulcer healing, relieve symptoms, and prevent ulcer recurrence.
Item | Specification | Test result |
Appearance | white powder | Conforms |
Assay | 99% | Conforms |
Heavy metal | ≤10ppm | Conforms |
Lead | ≤2.0ppm | Conforms |
As | ≤2.0ppm | Conforms |
Ca | ≤1.0ppm | Conforms |
Me | ≤0.1ppm | Conforms |
Total aerobic microbial count | ≤1000CFU/g | Conforms |
Total moulds&yeast count | ≤100CFU/g | Conforms |
Enterobacterial | ≤10MPN/g | Conforms |
Salmonella | N.D/25g | Conforms |
Escherichia coli | N.D/10g | Conforms |
Staphylococcus aureus | N.D/10g | Conforms |
Pseudomonas aeruginosa | N.D/10g | Conforms |
Conclusion: Conform with specification. |
Uses
Receptor antagonist, Lafutidine has a unique gastric protective effect. It can reduce the basal secretion of gastric acid and inhibit the gastric acid secretion stimulated by histamine, gastrin, and urethane. Compared with similar drugs such as cimetidine and famotidine, the blocking effect on H2 receptors is more effective and lasting, so it has the advantage of more sustained anti-gastric acid secretion effect. It is mainly used to treat gastric ulcers, duodenal ulcers and acute or chronic gastritis.